by | Apr 14, 2024 | Publications
Ann Hematol. 2024 Apr 13. doi: 10.1007/s00277-024-05730-y. Online ahead of print. ABSTRACT Improvement in the therapeutics for multiple myeloma (MM) has been continuously developed owing to the application of novel drugs and technologies in the last 20 years. The...
by | Apr 14, 2024 | Publications
Cancers (Basel). 2024 Mar 24;16(7):1263. doi: 10.3390/cancers16071263. ABSTRACT BACKGROUND: Multiple myeloma (MM) is a hematological neoplasm of the early precursor of B-cells. The most characteristic symptoms observed during MM include hypocalcemia, anemia, bacterial...
by | Apr 14, 2024 | Publications
Cancers (Basel). 2024 Mar 28;16(7):1319. doi: 10.3390/cancers16071319. ABSTRACT Progress in the treatment of multiple myeloma (MM) has resulted in improvement in the survival rate. However, there is still a need for more efficacious and tolerated therapies. We and...
by | Apr 14, 2024 | Publications
Int J Mol Sci. 2024 Mar 28;25(7):3799. doi: 10.3390/ijms25073799. ABSTRACT Multiple myeloma (MM) is a plasma cell disorder representing the second most common blood cancer […]. PMID:38612612 | DOI:10.3390/ijms25073799
by | Apr 14, 2024 | Publications
Int J Hematol. 2024 Apr 13. doi: 10.1007/s12185-024-03766-4. Online ahead of print. ABSTRACT Despite the development of various therapeutic agents, multiple myeloma remains incurable. Recently, T-cell redirected immunotherapy has become a promising strategy for the...
by | Apr 14, 2024 | Publications
Am J Hematol. 2024 Apr 13. doi: 10.1002/ajh.27327. Online ahead of print. ABSTRACT Multiple myeloma (MM) exhibits significant heterogeneity in its presentation, genetics, and treatment response. Despite therapeutic advances, some patients continue to relapse early...
